Phathom Pharma Upgraded by Barclays to Overweight $18 Target
Barclays lifts Phathom Pharmaceuticals to Overweight with an $18 target, citing a stronger 2026 revenue trajectory an...
Learn which credit cards provide fuel rewards without fees. Maximize your savings on gas effortlessly.
23,328 articlesBarclays lifts Phathom Pharmaceuticals to Overweight with an $18 target, citing a stronger 2026 revenue trajectory an...
Bitcoin dropped below the $67,000 level as U.S. Treasury yields climbed toward yearly highs, igniting a risk-off shak...
Schwab’s U.S. Dividend Equity ETF has a notable energy stake that’s helped its performance. This article explains wha...
Rem’s Mortgage REIT Portfolio surged 19% over the past year as the Fed signaled a slower stance on rates, lifting inc...
Dogecoin broke through a multi-session resistance with a heavy volume burst, prompting traders to eye the next hurdle...
Retirement planning goes beyond a bank balance. This guide shows how to retire with confidence by aligning money, hea...
Deficits are mounting as the Treasury plots heavy borrowing for the current and next fiscal years. Officials project ...
Uber’s first-quarter results sparked a rare split on Wall Street: Goldman Sachs trims the stock target, while Piper S...
Griffon (GFF) 2026 earnings season offers clues about growth and margins across its portfolio. This guide breaks down...
With quantum threats rising, bitcoin developers might permanently consider a staged freeze of Satoshi’s legendary sta...
AI-driven payroll reductions accelerate as major firms trim jobs, altering earnings and market sentiment in May 2026.
Rocket Lab rockets higher after a record Q1 FY2026 showing strong revenue and a bloated backlog, signaling momentum f...